Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Pharmacological management of COVID-19 in type 2 diabetes

Antonio Ceriello *, Francesco Prattichizzo *

IRCCS MultiMedica, Milan, Italy

A R T I C L E   I N F O

Article history:
Received 16 March 2021
Received in revised form 8 April 2021
Accepted 8 April 2021
Available online 17 April 2021

Keywords:
ACE2
Cardiovascular disease
Corticosteroids
COVID-19
Diabetes
Guidelines
Hydroxychloroquine
Hyperglycemia
SARS-CoV-2
Thrombosis

A B S T R A C T

Evidence suggests that diabetes is one of the most relevant comorbidities in affecting the prognosis of COVID-19. Although there are no specific trials nor subgroup analysis showing the effect of COVID-19 therapies in patients with diabetes, selected features of this disease and the side effects associated with certain drugs require a proper knowledge to optimize the pharmacological therapy of patients with diabetes and COVID-19. While chronic anti-hypertensive and glucose-lowering therapies should not be discontinued nor preferred for preventive purposes, the low-grade pro-inflammatory, the thrombosis-prone status of diabetes, the role of acute hyperglycaemia in promoting adverse outcomes in patients admitted to ICU, and the observed increased mortality in patients with poor long-term glycaemic control delineate a delicate balance in case of severe forms of COVID-19. Here, we briefly summarized some of the key pharmacological issues linked to the management of patients with diabetes and COVID-19, in order to provide indications to minimize the deleterious effects of the concomitant presentation of these diseases and to use the existing pharmacological options in an appropriate manner.

© 2021 Elsevier Inc. All rights reserved.

1. Introduction

Coronavirus disease (COVID)-19, the infectious disease caused by SARS-CoV-2, has spread all over the world. Diabetes has emerged as one of the most important comorbidities in affecting the prognosis of people with COVID-19. Diabetes, and in particular type 2 diabetes, is characterized by a pervasive status of low-grade inflammation, the presence of multiple comorbidities, and a thrombosis-prone profile. These predispose patients with diabetes to develop a severe hyperinflammatory reaction, coagulation abnormalities, and multi-organ failure, usually underlying the most severe forms of COVID-19. On the other side, some anti-inflammatory drugs, e.g., corticosteroids, are known to worsen glycaemic control in people with diabetes, a phenomenon that should be avoided in patients admitted to ICU. Hyperglycaemia at hospital admission has been linked to an increased death rate in COVID-19 patients with and without diabetes. In addition, SARS-CoV-2 infection per se has been suggested to promote and aggravate the diabetic condition, given the ability of the virus to promote both systemic acute inflammatory responses, likely causing insulin resistance, but also β-cells deterioration. These considerations delineate a delicate balance between the potential benefits and harms of pharmacological therapies in patients with the concomitant presentation of diabetes and COVID-19.

In this article, we synthesize key pharmacological aspects of the management of COVID-19 in patients with diabetes, focusing on both the chronic therapies, i.e. the anti-hypertensive and the glucose-lowering, and the drugs used for the management of patients in case of infection, i.e. the anti-inflammatory (hydroxychloroquine, corticosteroids, and the anti-cytokine biologicals), the antivirals, and the anti-coagulant ones.

2. Chronic therapies- anti-hypertensives and glucose-lowering therapies

Angiotensin-Converting-Enzyme-2 (ACE2) receptors have been identified as the receptors for the spike-protein of the "Severe acute respiratory syndrome coronavirus 2" (SARS-CoV-2). A serious concern, particularly for diabetes, about a possible induction of the ACE2 was suggested related to the use of ACEi or ARBs. Both ACEi and ARB with SARS-CoV-2 infection are widely used for the treatment of hypertension and different kidney diseases, two conditions very often present in diabetes. Specific studies have later confirmed that these drugs are neutral or even somehow neutral.
helpful during the COVID-19, thus suggesting that suspending such therapies has no benefit in preventing severe forms of COVID-19. This applies also to patients with diabetes. Rather, mechanistic hypotheses suggest that drug discontinuation in case of infection can eventually promote adverse outcomes through a detrimental effect on ACE1/AEC2 balance. On the contrary, an ongoing trial will test if introducing de novo an ACEi in case of infection can be helpful to attenuate COVID-19 outcomes (NCT04360650).

Inflammation plays a key role during the SARS-CoV-2 infection. The Dipeptidyl Peptidase 4 receptor (DPP4) is expressed ubiquitously in many tissues, including in the respiratory tract, where it cleaves a large range of protein substrates, including cytokines and chemokines. DPP4 was also suggested to be the functional receptor of other human coronaviruses, thus representing a potential target to reduce the severity of the COVID-19 by attenuation of both viral spreading and of the inflammatory response. DPP4 is the target of incretin-based therapies, and this opened the discussion whether DPP4-inhibitors, currently used for the treatment of people with type 2 diabetes, may be effective against SARS-CoV-2 infection. Recent data from observational studies have shown both a beneficial or a neutral effect of DPP-4 inhibitors on COVID-19 related mortality. Worth mentioning, a genetic variant within the gene encoding for DPP9, a serine protease of the same family of DPP4, is associated with severe forms of COVID-19, while diverse DPP4 inhibitors have different selectivity among various DPP, with divergent effects on immune cells activation. Two ongoing trials are exploring if DPP-4 inhibitor treatment on top of the insulin regimen can help to ameliorate the severity of the COVID-19. 

It has been hypothesized that the Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), the Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might induce an over-expression of the ACE2, therefore increasing the risk for more serious consequences for people with diabetes if infected. The alarm has not been justified; on the contrary all the above-mentioned drugs for the treatment of diabetes also show very good anti-inflammatory action and, in the case of GLP-1RAs and SGLT-2i, proven cardiovascular and renal protection. Recent data from large observational cohorts showed a neutral effect in terms of COVID-19 related mortality in patients initiating such drugs, while metformin and insulin users showed, respectively, a decreased and an increased COVID-19 related mortality. Whether these effects are drug-intrinsic or simply reflect the use of different drug classes at different stages of diabetes progression is matter of investigation. An ongoing trial is testing if the SGLT-2 inhibitor dapagliflozin is able to attenuate the progression of COVID-19 in patients with or without diabetes (NCT04350593). However, at present there are no data to justify a change in the glucose-lowering regimen for preventive purposes against COVID-19 in patients with diabetes, nor any drug should be added to the treatment schedule in case of infection. Also, ambulatory treatment should not be suspended in case of mild COVID-10.

3. Complications–hyperglycemia– impact and management & thrombosis

As reported above, diabetes is one of the most common comorbidities of severe COVID-19. However, what is intriguingly emerging is that beyond diabetes itself and the long-term glycemic control, the level of hyperglycemia at the time of the hospital admission for COVID-19 is conditioning a worse prognosis. Hyperglycemia exposes at higher risk of complicated COVID-19, particularly in people without previous diabetes or with diabetes discovered at the hospitalization, a condition being explored also to ascertain if COVID-19 itself can trigger the development of diabetes due to β-cells disruption. Furthermore, some studies also report that glucose variability, on top of the acute hyperglycemia, may have a damaging effect. These findings suggest that acute hyperglycemia, in addition to long-term glycaemic control, may play a key role in worsening the prognosis of people with COVID-19. In addition, short-term glycemic control might improve the prognosis of patients with diabetes hospitalized for COVID-19, albeit it cannot be firmly established whether acute hyperglycemia is an etiological factor driving poor prognosis or simply reflect disease severity. Of note, the deleterious effect of acute hyperglycemia in diabetes, more than the previous glycemic control, was previously shown in the Intensive Care Unit (ICU) setting, where an increased gap between admission glucose and HbA1c-derived average glucose levels has been demonstrated to be a predictor of mortality in critically ill patients with diabetes. The damaging impact of acute hyperglycemia and the effect of glucose variability were both already documented before the COVID pandemic. Moreover, it also well known that acute hyperglycemia in the ICU is more dangerous for people without diabetes than for people with diabetes.

However, excluding some recommendations released by the experts in diabetes, in the available National and International professional guidelines and expert recommendations (accessed and examined through PubMed accessed on October 20 18th 2020) the problem of diabetes and, particularly of the need for a strict control of hyperglycemia, is neglected. Continuous glucose monitoring should be mandatory to ensure stable metabolic compensation. Patients in the ICU requiring therapy for glycemic control should be handled solely by intravenous insulin using exact dosing with a perfusion device. A recommendation deriving from historical trial showing a reduction in short-term morbidity and mortality in critically ill adults targeted to lower blood glucose levels with insulin, independently of the etiological factor promoting ICU admission and valid also for patients without diabetes. 

Thrombosis emerged as one of the most important complication of COVID-19 and high dose anticoagulants treatment has been shown to be live-saving. 

Diabetes is characterized by a thrombosis-prone status. Hyperglycemia is a pro-thrombotic factor by itself, and this is particularly true in the case of acute hyperglycemia or glucose variability. These aspects of diabetes were initially not taken into account in COVID-19 management. It is worth remembering that acute hyperglycemia induces an activation of coagulation also in people without diabetes. This phenomenon, which is driven by oxidative stress generation, is also accompanied by the induction of inflammation and endothelial dysfunction, which, together, may precipitate a cardiovascular event and promote other detrimental outcomes, particularly in the case of the COVID-19. Prophylactic anti-coagulant therapy should represent a routine approach to manage patients with diabetes and COVID-19.

4. Management of infection

4.1. Corticosteroids

The use of corticosteroids was not recommended at the beginning of the COVID-19 pandemic. This was also the official position of the WHO. This recommendation was mainly driven by the previous experience with influenza, SARS-CoV-1, or MERS-CoV. COVID-19 is characterized by an intense inflammatory reaction; therefore, corticosteroid treatment could have had an important role to suppress lung and other tissues inflammation. The recent publication of the RECOVERY Study shows that the use of Dexamethasone decreases mortality in people affected by severe forms of COVID-19, albeit contradictory findings have also been reported. 

On the other side, data seem to show that the use of corticosteroids in people with diabetes is accompanied by a worse prognosis. In the same studies, however, it is also confirmed the deleterious effect of hyperglycemia on the outcomes of the disease. A possible explanation is that the use of corticosteroids impacts on the levels of glycemia and that, probably, the advantages of using them may be lost because of the damage induced by hyperglycemia. While definitive data
regarding the usefulness of using corticosteroids in patients with diabetes and COVID-19 are not available at present, this consideration further emphasizes the need of frequent glycemic monitoring and control in patients with diabetes and COVID-19, especially when corticosteroids therapy is introduced.

4.2. Hydroxychloroquine

Preliminary evidence suggested a potential benefit of using hydroxychloroquine in the COVID-19, until two publications suggested the uselessness of this treatment.61 The data of two papers were questioned for serious methodological issues revealed after their publication62,63 and the possible benefits of this treatment are still under research.64 During this “debate” hydroxychloroquine use was still promoted by media. Reports of success in early clinical studies were widely publicized by news outlets, politicians and on social media.65 However, hydroxychloroquine may have serious adverse effects, particularly for the heart.66 It is well known that cardiovascular diseases very often accompany diabetes, so the use of hydroxychloroquine might have exposed people with diabetes at higher risk of complications. Moreover, hydroxychloroquine is increasing the risk of hypoglycemia,75 which itself is a serious risk factor for cardiovascular complications.69 Albeit no trial tested the effect of hydroxychloroquine specifically in patients with COVID-19 and diabetes, results from large trials showed no benefit in terms of reduced mortality and an increased incidence of serious adverse events in patients with COVID-19 treated with such drug.69 Given the latest recommendations regarding hydroxychloroquine and COVID-19, this aspect should no longer represent a concern.

4.3. Remdesivir

Remdesivir is the only FDA approved anti-viral drug for the treatment of severe forms of COVID-19.70 While the WHO-conducted trial showed no benefit in terms of survival in patients with COVID-19,71 another study showed a shortening in the time to recovery in hospitalized adults and a nonsignificant trend also for improved survival at day 29 from hospitalization.72 While the discussion regarding its benefit for COVID-19 management is far from being closed, remdesivir is being used in clinical practice in patients with severe forms of the disease. None of the two available studies71,72 showed data for the subgroup of patients with diabetes, precluding the exploration of its effect in this specific setting. However, remdesivir is known to promote liver and kidney damage.70 Given the high prevalence of both liver, e.g. non-alcoholic fatty liver disease, and kidney, e.g. diabetic nephropathy, diseases in patients with diabetes, it is of utmost importance to evaluate the presence of these comorbidities and to monitor liver and kidney function when the therapy is introduced.

4.4. Ivermectin

Ivermectin is being prescribed as a potential treatment for COVID-19, especially in patients with mild forms of the disease. Previous pre-clinical work showed a potential glucose-lowering effect for ivermectin,73 albeit no data substantiated such observation in humans. While there are no available data for ivermectin use in patients with diabetes and COVID-19, a recent trial showed no benefit for a 5-day course of ivermectin in patients with mild COVID-19, prompting the regulatory agencies to recommend against its routine use.74,75

4.5. Anti-cytokines biologicals

COVID-19 patients, especially those experiencing the worst outcomes, are often accompanied by an overwhelming inflammatory reaction, usually referred to as “cytokine storm”. This phenomenon is further enhanced by pre-existing comorbidities, as in the case of type 2 diabetes.76 A number of trials are testing if targeting major cytokines with existing anti-cytokine biologicals in COVID-19 patients provides benefit in terms of mortality or other outcomes.77 Diffuse, rationale-based use of such drugs is being done in hospitalized patients with COVID-19.4 As mentioned above, diabetes, and especially type 2 diabetes, has a pervasive inflammatory component in its etiopathogenesis.5,76 Thus, it is not surprising that a number of anti-inflammatory drugs, including anti-cytokines biologicals, have showed a certain degree of glucose-lowering effect in both patients with and without diabetes,78 as well as substantiated by clinical trials.79 In particular, this applies also to tocilizumab (anti-IL-6), anakinra (anti-IL-1 receptor), and multiple TNF-α inhibitors, i.e. frequently used drugs in patients with COVID-19.80,78 However, the magnitude of the glucose-lowering effect should not represent a concern relative to the risk of hypoglycemia.6 Rather, such drugs are expected to be particularly beneficial in severe COVID-19 patients with diabetes, as well as with other diseases characterized by low-grade inflammation.80 However, no specific data relative to the effect of these drugs in the subgroup of patients with diabetes and COVID-19 are available, with the exception of epidemiological findings suggesting a decreased COVID-19-related mortality rate in subjects with diabetes and on treatment with TNF-α inhibitors prior to infection.25

4.6. Convalescent plasma and monoclonal antibodies therapies

The use of plasma from convalescent patients was proposed from the beginning as a treatment to halt virus progression and limit the consequences of COVID-19, so the FDA authorized its use as an investigational drug in this context.79 RCTs and other studies have provided contrasting results. As a result, three meta-analysis found a consistent benefit81,82 a low-quality evidence for mortality reduction82 and no substantial benefit on a range of possible outcomes,83 respectively. Type 2 diabetes is accompanied by a range of alterations relative to the immune system, which underlie a higher susceptibility to selected infections and a blunted antibody response to vaccination.83 Thus, it might be hypothesized that patients with type 2 diabetes are among those benefitting most by convalescent plasma therapy. One small cohort study exploring the effect of convalescent plasma in patients with type 2 diabetes showed that, when compared to a matched cohort with similar clinical characteristics on conventional therapy, patients treated with convalescent plasma had a higher rate of discharge from the hospital, with only few and non-serious adverse events reported.85 Given that the rationale underpinning the use of monoclonal antibodies is the same, similar results might be expected. At present, monoclonal antibodies have been tested only in patients with early and mild COVID-19, providing preliminary results in terms of reduction of viral load and subsequent rate of hospitalization.86 No data are available specifically for patients with diabetes. However, this should not represent any contraindication for the use of such drugs.

5. Concluding remarks

People with diabetes are among those with an increased risk of death in case of COVID-19.1 Myocardial injury is a very frequent complication of COVID-19, being more frequent in people with a previous cardiovascular disease.87 This last condition is very often present in people with diabetes and on treatment with TNF-α inhibitors,6 with diabetes and COVID-19 especially when corticosteroids therapy is introduced.

The use of plasma from convalescent patients was proposed from the beginning as a treatment to halt virus progression and limit the consequences of COVID-19, so the FDA authorized its use as an investigational drug in this context.80 RCTs and other studies have provided contrasting results. As a result, three meta-analysis found a consistent benefit81,82 a low-quality evidence for mortality reduction82 and no substantial benefit on a range of possible outcomes,83 respectively. Type 2 diabetes is accompanied by a range of alterations relative to the immune system, which underlie a higher susceptibility to selected infections and a blunted antibody response to vaccination.83 Thus, it might be hypothesized that patients with type 2 diabetes are among those benefitting most by convalescent plasma therapy. One small cohort study exploring the effect of convalescent plasma in patients with type 2 diabetes showed that, when compared to a matched cohort with similar clinical characteristics on conventional therapy, patients treated with convalescent plasma had a higher rate of discharge from the hospital, with only few and non-serious adverse events reported.85 Given that the rationale underpinning the use of monoclonal antibodies is the same, similar results might be expected. At present, monoclonal antibodies have been tested only in patients with early and mild COVID-19, providing preliminary results in terms of reduction of viral load and subsequent rate of hospitalization.86 No data are available specifically for patients with diabetes. However, this should not represent any contraindication for the use of such drugs.

5. Concluding remarks

People with diabetes are among those with an increased risk of death in case of COVID-19.1 Myocardial injury is a very frequent complication of COVID-19, being more frequent in people with a previous cardiovascular disease.87 This last condition is very often present in people with diabetes and on treatment with TNF-α inhibitors,6 with diabetes and COVID-19 especially when corticosteroids therapy is introduced.

The use of plasma from convalescent patients was proposed from the beginning as a treatment to halt virus progression and limit the consequences of COVID-19, so the FDA authorized its use as an investigational drug in this context.80 RCTs and other studies have provided contrasting results. As a result, three meta-analysis found a consistent benefit81,82 a low-quality evidence for mortality reduction82 and no substantial benefit on a range of possible outcomes,83 respectively. Type 2 diabetes is accompanied by a range of alterations relative to the immune system, which underlie a higher susceptibility to selected infections and a blunted antibody response to vaccination.83 Thus, it might be hypothesized that patients with type 2 diabetes are among those benefitting most by convalescent plasma therapy. One small cohort study exploring the effect of convalescent plasma in patients with type 2 diabetes showed that, when compared to a matched cohort with similar clinical characteristics on conventional therapy, patients treated with convalescent plasma had a higher rate of discharge from the hospital, with only few and non-serious adverse events reported.85 Given that the rationale underpinning the use of monoclonal antibodies is the same, similar results might be expected. At present, monoclonal antibodies have been tested only in patients with early and mild COVID-19, providing preliminary results in terms of reduction of viral load and subsequent rate of hospitalization.86 No data are available specifically for patients with diabetes. However, this should not represent any contraindication for the use of such drugs.

5. Concluding remarks

People with diabetes are among those with an increased risk of death in case of COVID-19.1 Myocardial injury is a very frequent complication of COVID-19, being more frequent in people with a previous cardiovascular disease.87 This last condition is very often present in people with diabetes and on treatment with TNF-α inhibitors,6 with diabetes and COVID-19 especially when corticosteroids therapy is introduced.

The use of plasma from convalescent patients was proposed from the beginning as a treatment to halt virus progression and limit the consequences of COVID-19, so the FDA authorized its use as an investigational drug in this context.80 RCTs and other studies have provided contrasting results. As a result, three meta-analysis found a consistent benefit81,82 a low-quality evidence for mortality reduction82 and no substantial benefit on a range of possible outcomes,83 respectively. Type 2 diabetes is accompanied by a range of alterations relative to the immune system, which underlie a higher susceptibility to selected infections and a blunted antibody response to vaccination.83 Thus, it might be hypothesized that patients with type 2 diabetes are among those benefitting most by convalescent plasma therapy. One small cohort study exploring the effect of convalescent plasma in patients with type 2 diabetes showed that, when compared to a matched cohort with similar clinical characteristics on conventional therapy, patients treated with convalescent plasma had a higher rate of discharge from the hospital, with only few and non-serious adverse events reported.85 Given that the rationale underpinning the use of monoclonal antibodies is the same, similar results might be expected. At present, monoclonal antibodies have been tested only in patients with early and mild COVID-19, providing preliminary results in terms of reduction of viral load and subsequent rate of hospitalization.86 No data are available specifically for patients with diabetes. However, this should not represent any contraindication for the use of such drugs.
strategy to manage patients with diabetes and COVID-19, until specific evidence regarding optimal therapy in this setting is available.

Funding
This work has been supported by the Italian Ministry of Health - Ricerca Corrente to IRCCS Multimedica.

Ethical statement
This is a narrative review and, as such, no raw data were generated.

CRediT authorship contribution statement
AC and FP made the literature search and wrote the manuscript.

Declaration of competing interest
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References
1. Caballero AE, Ceriello A, Misra A, et al. COVID-19 in people living with diabetes: An international consensus. J Diabetes Complications 2020;34:107671.
2. Ceriello A. Coagulation activation in diabetes mellitus: the role of hyperglycaemia and therapeutic prospects. Diabetologia 1993;36:1119-25.
3. Ceriello A, De Nigris V, Prattichizzo F. Why is hyperglycaemia worsening COVID-19 and its prognosis? Diabetes Obes Metab 2020. https://doi.org/10.1111/dom.14096.
4. Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol 2021;17:11-30.
5. Prattichizzo F, Galluzzo S, Matarrese G. T cell warriors: victims of SARS-CoV-2 infection. Trends Immunol 2020 Nov 13;31(6):1068-1077.e3. S1471-4906(20)30269-X.
6. Liu Z, Shi ZG, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020;31:1068-77.
7. Wolls AC, Park YJ, Tortorici AM, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020;181:281-92.
8. Paranjpe I, Fuster V, Lala A, et al. Association of treatment dose anticoagulation with thromboembolism in patients with COVID-19: a prospective cohort study. Ann Intern Med 2020;173:268-77.
9. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813-21.
10. Wu J, Huang J, Zhu C, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BJM Open Diabetes Res Care 2020;8,e001476.
11. Singh AK, Singh R. Hyperglycaemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract 2020;108382.
12. Bolli R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Metab Syndr Obes 2020;13:1068-77.
13. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R. Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010;8:1663-9.
14. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists. Virchows Arch 2020;476:525-36.
15. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycaemia affected by COVID-19: can we do more on glycemic control? Diabetes Res Clin Pract 2020;148:105-18.
16. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813-21.
17. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European pulmonary pathologists. Virchows Arch 2020;476:525-36.
18. Brancatelli G, Specchio F, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycaemia affected by COVID-19: can we do more on glycemic control? Diabetes Res Clin Pract 2020;148:105-18.
19. Bode B, Garrett V, Messler J, et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J Diabetes Sci Technol 2020;14:813-21.
20. Wu J, Huang J, Zhu C, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BJM Open Diabetes Res Care 2020;8,e001476.
21. Agarwal S, Schechter C, Southern W, Crandall JP, Tomer Y. Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019. Diabetes Care 2020;43(10):e339-44. d201543.
22. Fadini P, Morieri M, Rosari F, et al. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetologia 2020;63:1500-15.
23. Brancatelli G, Specchio F, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycaemia affected by COVID-19: can we do more on glycemic control? Diabetes Res Clin Pract 2020;148:105-18.
24. Bolli R, Bhansali A. COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Metab Syndr Obes 2020;13:1068-77.
25. Ceriello A, Giugliano D, Quatraro A, Dello Russo P, Marchi E, Torella R. Hyperglycemia may determine fibrinopeptide a plasma level increase in humans. Metabolism 1989;38:1162-3.
53. Russell CD, Millar JE, Baille JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.

54. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA 2020;323:1824-36.

55. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. World Health Organization, Geneva Jan 28, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed February 2, 2020.

56. Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol 2020;11:i708.

57. Horby P, Lim WS, Emberson JR, et al, RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with COVID-19 - Preliminary report. N Engl J Med 2020;384:693-704. NEJMoa201436.

58. Chatterjee K, Wu CP, Bhardwaj A, Siuba M. Steroids in COVID-19: an overview. Cleve Clin J Med 2020. https://doi.org/10.3949/ccjm.87a.ccc059.

59. Xu Z, Wang Z, Wang S, et al. The impact of type 2 diabetes and its management on the prognosis of patients with severe COVID-19. J Diabetes 2020. https://doi.org/10.1111/1753-0407.13084.

60. Mittal S, Madan K, Mohan A, Tiwari P, Hadda V. Diabetes in COVID-19: steroid effect. J Med Virol 2020. https://doi.org/10.1002/jmv.25457.

61. Cortegiani A, Ippolito M, Ingoglia G, et al. Update I: a systematic review on the efficacy and safety of chloroquine/hydroxychloroquine for COVID-19. J Crit Care 2020;59:176-90.

62. Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 2020;382:2411-8.

63. Mehra MR, Desai SS, Ruschitzka F, Patel AN. RETRACTED; hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020;395:1820.

64. Hernandez AH, Roman YM, Pasupuleti V, Barboza JJ, White CM. Update alert 2: hydroxychloroquine or chloroquine for the treatment or prophylaxis of COVID-19. Ann Intern Med 2020;120:1054.

65. Islam MS, Sarkar T, Khan SH, et al. COVID-19-related infodemic and its impact on public health: a global social media analysis. Am J Trop Med Med Hyg 2020. https://doi.org/10.4269/ajtmh.20-0812.

66. Stevenson A, Kirresh A, Conway S, et al. Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified? Open Heart 2020;7:e001362.

67. Stoian AP, Catrimou D, Rizzo M, Cerriello A. Hydroxychloroquine, COVID-19 and diabetes. Why it is a different story. Diabetes Metab Res Rev 2020;37(7), e3379.

68. Valensi P, Prévost G, Schnell O, Standl E, Ceriello A. Targets for blood glucose: what have the trials told us. Eur J Prev Cardiol 2019;26:25-32.

69. Self WH,Semler MW,Leitner LM,et al. Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial. JAMA 2020 Dec 1;324:2165-76.

70. “Fact Sheet for Patients And Parent/Caregivers Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)” (PDF). U.S. Food and Drug Administration (FDA).

71. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med 2020 Dec 2. https://doi.org/10.1056/NEJMoA2031894.

72. Beigel JH, Tomashek KM, Dodd LE, et al. ACTT-1 study group members. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med 2020 Nov 5;383:1813-26. https://doi.org/10.1056/NEJMoA2007764.

73. Jin L, Feng X, Rong H, et al. The antiparasitic drug ivermectin is a novel FXR ligand that regulates metabolism. Nat Commun 2013;4:1937.

74. López-Medina E, López P, Hurtado IC, et al. Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical Trial. JAMA March 04, 2021;325(14):1426-35. Published online.

75. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials.

76. Bonafé M, Prattichizzo F, Giuliani A, Storci G, Sabbatinelli J, Olivieri F. Inflamm-aging: why older men are the most susceptible to SARS-CoV-2 complicated outcomes. Cytokine Growth Factor Rev 2020 Jan;53:33-7.

77. Cavalli G, Larcher A, Tomelleri A, et al. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatol 2021 Feb 3. https://doi.org/10.1016/S2665-9913(21)00012-6.

78. Pollack RM, Donath MY, LeRoith D, Leibowitz G. Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 2016 Aug;39:5244-52.

79. Larsen CM, Faulenzbach M, Vaag A, Velund A, Ehes JAM, Seifert B, et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007 Apr 12;356:1517-26.

80. https://www.fda.gov/vaccines-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma.

81. Klassen SA, Senefeld JW, Johnson PW, et al. The effect of convalescent plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clin Proc 2021 In press.

82. Sarkar S, Soni KD, Khanna P. Convalescent plasma is a clutch at straws in COVID-19 management! A systematic review and meta-analysis. J Med Virol 2021;93:1111-8.

83. Chai KL, Valk SJ, Pechotta V, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev 2020;10.

84. de Candia P, Prattichizzo F, Garavelli S, et al. Type 2 diabetes: how much of an autoimmune disease? Front Endocrinol (Lausanne) 2019 Jul 4;10:451.

85. Dai W, Wu J, Li T, et al. Clinical outcomes for COVID-19 patients with diabetes mellitus treated with convalescent plasma transfusion in Wuhan. China J Med Virol 2021;93:2321-31.

86. Cohen MS. Monoclonal antibodies to disrupt progression of early Covid-19 infection. N Engl J Med 2021 Jan 21;384:289-91.

87. Lala A, Johnson KW, Januzzi JL, et al. Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection. Mount Sinai COVID-19 informatics center; J Am Coll Cardiol 2020;76:533-46.

88. Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019;26:25-32.